Axsome Therapeutics
@axsomeTurning patient needs into breakthrough discoveries.
Similar User
@AlectorTx
@SamvanRooy1
@VeronaPharma
@ZymeworksInc
@bbgconnects
@AmylyxPharma
@theWondry
@Seegene_HQ
@GaleTStrong
@mljmljmlj
@NeumoraTx
@neurocrine
@longeviti
@SDCFAR
@Emmanue58661079
We are sharing data from across our leading neuroscience pipeline at NEI Congress. Come and meet our team at the posters or at Booths 405, 505, and 897. Learn more about the presentations here: bit.ly/48JJHiF #NEIcongress
We have seven presentations from across our broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024. Come and meet with us at the conference and learn more about the presentations here: bit.ly/3A7mpGZ #PsychCongress2024
We’re honored to stand with the global narcolepsy community to show support on World Narcolepsy Day. You can learn more about narcolepsy and #WorldNarcolepsyDay here: bit.ly/4eB4czN
This morning we announced that the FDA acknowledged the resubmission of our New Drug Application (NDA) for AXS-07 for the acute treatment of migraine and set a PDUFA action goal date of January 31, 2025. Read more about the news here: bit.ly/4gg5Msz
Come and join a thriving team working to make a meaningful difference in the lives of people affected by hard-to-treat CNS disorders. You can learn about our featured open roles in the video below and see all our open roles here: bit.ly/3s2Ykwx #hiring
Behavioral symptoms of Alzheimer’s disease, such as agitation, are reported in up to 70% of all patients with Alzheimer’s disease. Learn more about resources available for people with Alzheimer’s and their loved ones here: bit.ly/3Xda1yh #AlzheimersAwarenessMonth
Looking to make a difference? Check out these open roles where you can join a team on a mission to improve the lives of people with hard-to-treat CNS disorders. Learn about our featured open roles in the video below and see all our open roles here: bit.ly/3s2Ykwx #hiring
More than 37 million Americans suffer from migraine disorder making it one of the leading causes of disability amongst neurological disorders in the U.S. Check here to learn more about migraine and available resources: bit.ly/3VsJrzG #MigraineAwareness #MHAM2024
Alzheimer’s disease is the most common form of dementia, affecting nearly 7 million people in the United States alone. Learn more about resources available for people with Alzheimer’s and their loved ones here: bit.ly/3Xda1yh #AlzheimersAwarenessMonth
We have five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024. Come and meet us at the conference and check here to learn more about the presentations: bit.ly/4e3AoN5 #SLEEP2024
Please join us at the American Society of Clinical Psychopharmacology (@ASCPorg) Annual Meeting for multiple data presentations. Learn more about the presentations here: bit.ly/4dVsnJX #ASCP2024
This year for Fibromyalgia Awareness Day we are sharing resources to help support the 5 million people affected by fibromyalgia in the United States and to educate others. Learn more about fibromyalgia here: bit.ly/3UxGDQ0 #FibromyalgiaAwarenessDay #Fibromyalgia
Fewer than half of U.S. adults with mental illness received treatment in 2021. Many free online resources and tools are available to provide support for people with mental illness. Learn about mental health and available resources here: bit.ly/3WvvAK1 #MentalHealthMonth
#MentalHealth conditions are extremely prevalent in the United States, affecting almost half of the population. Axsome is developing novel therapies for some of the hardest to treat mental health conditions. Learn more about our R&D efforts here: bit.ly/3wgwHCx
Please join us at the 2024 American Academy of Neurology (AAN) Annual Meeting where we have presentations that highlight our innovative neuroscience portfolio. Learn more about our presentations at AAN here: bit.ly/3W3cRVN #AANAM #psychiatry #neurology
Join a rapidly growing team where you can help to advance novel treatments for some of the most challenging CNS disorders. Learn about our featured open roles in the video below and see all our open roles here: bit.ly/3s2Ykwx #hiring
The first week of April is APHA’s (@PublicHealth) National Public Health Week. This year’s theme is “Protecting, Connecting and Thriving” and is focused on how public health is about more than just health care alone. For more info, visit: nphw.org #NPHW
We are pleased to announce the initiation of the ENGAGE Phase 3 trial in binge eating disorder, the most common eating disorder. Please read here to learn more: bit.ly/43KHz7V #BingeEating
We are pleased to announce positive topline data from the SYMPHONY Phase 3 trial in narcolepsy. Please read the full release for more details: bit.ly/3TyCpHv#narcol…
We are pleased to announce that the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol as a potential treatment for adults with major depressive disorder. Please read here to learn more: bit.ly/493YIdT #depression #MDD
United States Trends
- 1. Rashford 26,7 B posts
- 2. Geraldo 7.408 posts
- 3. Amorim 97,6 B posts
- 4. Southampton 65,4 B posts
- 5. #AskFFT N/A
- 6. Liverpool 164 B posts
- 7. Go Birds 2.934 posts
- 8. Amad 24,5 B posts
- 9. Mo Salah 25,3 B posts
- 10. #RollWithUs 1.195 posts
- 11. #sundayvibes 11 B posts
- 12. Xcretion N/A
- 13. #MUFC 48,5 B posts
- 14. Good Sunday 75,7 B posts
- 15. #AskZB N/A
- 16. Garnacho 16,2 B posts
- 17. Sesame Street 3.011 posts
- 18. Dalot 7.877 posts
- 19. Eriksen 5.838 posts
- 20. Chuck Woolery 17,7 B posts
Who to follow
-
Alector
@AlectorTx -
Sam van Rooy MP
@SamvanRooy1 -
Verona Pharma
@VeronaPharma -
Zymeworks Inc.
@ZymeworksInc -
Bloomberg Connects
@bbgconnects -
Amylyx
@AmylyxPharma -
the Wond'ry
@theWondry -
Seegene
@Seegene_HQ -
Gale Turner Strong
@GaleTStrong -
Mary Lou Jepsen, PhD
@mljmljmlj -
Neumora
@NeumoraTx -
Neurocrine Biosciences
@neurocrine -
Longeviti Neuro Solutions
@longeviti -
SDCFAR_Science
@SDCFAR -
Emmanuel Sunday
@Emmanue58661079
Something went wrong.
Something went wrong.